Physician perspectives on a pilot prescription monitoring program

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 19, Issue 3, 2005, Pages 5-13

  Barrett, Kirsten ^a   Watson, Ashby ^b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Controlled substances; Pain; Physician prescribing behavior; Prescription Monitoring Program; State pain policy

Indexed keywords

OPIATE;

ANALGESIC AGENT ABUSE; CLINICAL PRACTICE; DATA BASE; DRUG SURVEILLANCE PROGRAM; HEALTH CARE ACCESS; HEALTH CARE QUALITY; HUMAN; INFORMATION PROCESSING; PAIN; PATIENT CARE; PHYSICIAN ATTITUDE; PRESCRIPTION; REVIEW; UNITED STATES;

ATTITUDE OF HEALTH PERSONNEL; AWARENESS; DRUG AND NARCOTIC CONTROL; GOVERNMENT REGULATION; HUMANS; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; NARCOTICS; PAIN; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS; PILOT PROJECTS; PRESCRIPTIONS, DRUG; QUESTIONNAIRES; SUBSTANCE-RELATED DISORDERS; VIRGINIA;

EID: 27944485651     PISSN: 15360288     EISSN: None     Source Type: Journal    
DOI: 10.1300/J354v19n03_03     Document Type: Review

References (18)

1. United States General Accounting Office. Prescription Drugs: State Monitoring Programs May Help to Reduce Illegal Diversion. Hearings Before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives. Report #GAO-04-524T. March 4, 2004.
2. Alliance of States with Prescription Monitoring Programs. The goals of prescription monitoring. Available at http://www.nascsa.org/alliance/Goals.pdf. Accessed January 28, 2005.
3. Institute of Medicine Committee on Care at the End of Life. Approaching death: Improving care at the end of life. Washington DC. National Academy Press, 1997.
4. Kaufman M. DEA withdraws its support of guidelines on painkillers. The Washington Post. Available at http://www.washingtonpost.com/wp-dyn/articles/ A49719-2004Oct20.html. Accessed October 24, 2004.
5. The American Alliance of Cancer Pain Initiatives. Statement on State Prescription Monitoring Programs, July 2002.
6. American Cancer Society. Position Statement on Regulatory Barriers to Quality Cancer Pain Management, October 2001.
7. Joranson DE, Carrow GM, Ryan KM, et al. Pain management and prescription monitoring. J Pain Symptom Manage. 2002;23(3):231-238.
8. Advisory Committee Meeting, Department of Health Professions, Prescription Monitoring Program Workplan, Roanoke, VA, December 10, 2003.
9. Virginia Department of Health Professions. Virginia prescription monitoring program. Available at http://www.dhp.state.va.us/dhp-programs/pmp/ default. asp. Accessed October 24, 2004.
10. Virginia Department of Health Professions. Title of Regulations: 18 VAC 76-20-10 et seq. Statutory Authority: § 54.1-2505 and § 54.1-2520 of the Code of Virginia.
11. Virginia Department of Health Professions. Virginia prescription monitoring program: Description of program. Available at http://www.dhp.state. va.us/dhp_ programs/pmp/pmp_desc.asp. Accessed February 3,2005.
12. Bureau of Justice Assistance. Harold Rogers prescription monitoring program. Available at http://www. ojp.usdoj.gov/BJA/grant/prescripdrugs. Accessed October 24, 2004.
13. Department of Health Professions Advisory Committee Meeting. Prescription Monitoring Program. Roanoke VA, December 10, 2003.
14. Sigler KA, Guernsey BG, Ingrim NB, et al. Effect of a triplicate prescription law on prescribing of schedule II drugs. Am J Hosp Pharm. 1984;41:108-111.
15. Berina LF, Guernsey BG, Hokanson JA, Doutre, WH, Fuller LE. Physician perception of a triplicate prescription law. Am J Hosp Pharm. 1985;42:857-859.
16. Weintraub M, Singh S, Byrne L, Maharaj K. Guttmacher L. Consequences of the 1989 New York State triplicate benzodiazepine prescription regulations. JAMA. 1991;266(17):2392-2397.
17. National Institute on Drug Abuse. Impact of Prescription Drug Diversion Control Systems on Medical Practice and Patient Care. NIDA Research Monograph 131.Rockville MD, 1993.
18. Wastila LJ. The influence of multiple copy prescription programs (MCPPs) on analgesic utilization. J Pharm Care Pain Symptom Control. 1996;4(3):3-19.